Pfizer
AI-Assisted Drug Discovery: Compressing Years of Research into Months
The Problem
Traditional drug discovery requires identifying candidate molecules from billions of possibilities, with each iteration of lab testing taking weeks and costing millions. The average drug takes 12+ years and $2.6B to bring to market, with a 90%+ failure rate.
The Solution
Pfizer partnered with AI companies to deploy generative molecular design models that propose novel drug-like molecules optimized for multiple properties simultaneously. ML models predict ADMET (absorption, distribution, metabolism, excretion, toxicity) properties to screen virtual compound libraries before physical synthesis.
The Outcome
Reduced initial hit identification from 4-6 years to under 12 months in pilot programs. AI-generated molecules showed superior properties in early screening. Applied these techniques to oncology and rare disease programs.
Key Metrics
- Hit identification time: 4-6 years → under 12 months
- Virtual screening of billions of molecular candidates
- 90%+ cost reduction in initial screening phase
- Applied to 15+ active drug discovery programs